Trevi Therapeutics
TRVI
13.14
-0.04
-0.30%
Trevi Therapeutics
US · TRVI
#2810 by market cap
Listed 2019
13.14
-0.04
-0.30%
Live - 5344 symbols - heartbeat 311s ago
· 2026-10-08 08:20
Pre-market
13.09
-0.40%
After-hours
13.14
0.00%
- Market cap
- 1.87B
- P/E (TTM)i
- -37.54
- P/Bi
- 5.82
- EPSi
- -0.32
- Div yieldi
- 0.00%
- 52W posi
- 35%
Reader sentiment
Are you bullish or bearish on TRVI?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.34M | 7.31M | 10.16M | 9.49M | 10.07M | 10.24M | 12.15M | 15.85M |
| Research & development | 14.07M | 19.34M | 22.33M | 22.98M | 19.83M | 23.68M | 39.38M | 33.48M |
| Operating profit | -18.41M | -26.65M | -32.49M | -32.48M | -29.91M | -33.92M | -51.52M | -49.33M |
| Pretax profit | -20.67M | -26.07M | -32.78M | -33.96M | -29.19M | -29.10M | -47.94M | -42.82M |
| Tax | -124.00K | -18.00K | -18.00K | -21.00K | -36.00K | -32.00K | -30.00K | -64.00K |
| Net profit | -20.55M | -26.05M | -32.76M | -33.94M | -29.15M | -29.07M | -47.91M | -42.76M |
| Basic EPS | -3 | -2 | -2 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -2.85 | -2.28 | -1.81 | -1.49 | -0.45 | -0.29 | -0.47 | -0.32 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.66M | 4.33M | 3.83M | 4.03M | 4.97M | 5.36M |
| Research & development | 7.81M | 9.39M | 10.09M | 6.19M | 9.94M | 15.15M |
| Operating profit | -11.47M | -13.72M | -13.92M | -10.22M | -14.91M | -20.51M |
| Pretax profit | -10.35M | -12.32M | -11.82M | -8.33M | -13.21M | -17.82M |
| Tax | -11.00K | -21.00K | -15.00K | -16.00K | -20.00K | -19.00K |
| Net profit | -10.34M | -12.30M | -11.80M | -8.32M | -13.19M | -17.80M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.09 | -0.09 | -0.08 | -0.06 | -0.09 | -0.11 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 8.82M | 59.55M | 46.27M | 37.96M | 122.62M | 87.55M | 109.43M | 191.66M |
| Cash & ST investments | 7.20M | 57.31M | 45.00M | 36.83M | 120.51M | 82.97M | 107.62M | 188.26M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 10.53M | 60.00M | 47.13M | 38.48M | 123.02M | 89.40M | 110.90M | 193.44M |
| Total current liabilities | 2.68M | 5.20M | 5.56M | 12.72M | 13.40M | 5.82M | 10.51M | 9.75M |
| Short-term debt | -- | 99.00K | 113.00K | 5.95M | 7.03M | 306.00K | 285.00K | 307.00K |
| Long-term debt | -- | -- | 13.95M | 8.65M | 2.15M | -- | -- | -- |
| Total liabilities | 4,278,000.00 | 5,456,000.00 | 19,849,000.00 | 21,400,000.00 | 15,556,000.00 | 6,856,000.00 | 11,256,000.00 | 10,195,000.00 |
| Total equity | 6.25M | 54.55M | 27.28M | 17.08M | 107.46M | 82.55M | 99.64M | 183.24M |
| Retained earnings | -109.50M | -114.22M | -146.98M | -180.92M | -210.07M | -239.13M | -287.05M | -329.80M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 105.62M | 207.23M | 198.30M | 191.66M | 176.12M | 325.71M |
| Cash & ST investments | 103.26M | 203.89M | 194.93M | 188.26M | 171.78M | 318.87M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 107.00M | 208.34M | 199.36M | 193.44M | 179.61M | 330.52M |
| Total current liabilities | 6.87M | 9.24M | 9.04M | 9.75M | 7.12M | 8.74M |
| Short-term debt | 276.00K | 286.00K | 296.00K | 307.00K | 318.00K | 329.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 7,547,000.00 | 9,846,000.00 | 9,568,000.00 | 10,195,000.00 | 7,479,000.00 | 9,012,000.00 |
| Total equity | 99.46M | 198.49M | 189.79M | 183.24M | 172.13M | 321.51M |
| Retained earnings | -297.39M | -309.69M | -321.49M | -329.80M | -343.00M | -360.79M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -18.29M | -23.09M | -29.00M | -28.95M | -28.18M | -31.71M | -38.26M | -42.09M |
| Depreciation & amortization | 23.00K | 39.00K | 47.00K | 50.00K | 43.00K | 123.00K | 147.00K | 144.00K |
| Free cash flow | -18.45M | -23.10M | -29.03M | -28.95M | -28.33M | -31.85M | -38.29M | -42.10M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -1.53M | 65.10M | 3.14M | 21.18M | 105.41M | 1.71M | 61.15M | 108.15M |
| Ending cash balance | 7.20M | 57.31M | 45.00M | 36.83M | 12.59M | 32.40M | 34.10M | 18.91M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -13.48M | -10.10M | -10.88M | -7.63M | -16.69M | -17.43M |
| Depreciation & amortization | 37.00K | 38.00K | 38.00K | 31.00K | 34.00K | 34.00K |
| Free cash flow | -13.48M | -10.10M | -10.89M | -7.63M | -16.79M | -17.55M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | -- | -- |
| Ending cash balance | 19.37M | 117.06M | 56.87M | 18.91M | 19.41M | 54.30M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -74.47 | -80.07 | -153.03 | -46.82 | -30.59 | -52.59 | -30.23 |
| ROA %i | -86.34 | -66.48 | -61.15 | -79.29 | -36.10 | -27.37 | -47.84 | -28.10 |
| ROIC %i | -- | -75.92 | -67.39 | -89.48 | -40.08 | -33.33 | -55.81 | -34.63 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -72.62 | -62.65 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.30 | 11.45 | 8.33 | 2.98 | 9.15 | 15.03 | 10.41 | 19.66 |
| Quick ratioi | 2.76 | 11.13 | 8.15 | 2.89 | 8.99 | 14.25 | 10.24 | 19.31 |
| Debt / assetsi | 0.44 | 0.59 | 30.15 | 38.02 | 7.46 | 1.50 | 0.93 | 0.39 |
| LT debt / equityi | -- | 0.47 | 51.68 | 50.81 | 2.00 | 1.25 | 0.75 | 0.24 |
| Interest coveragei | -117.79 | -- | -70.88 | -27.25 | -24.10 | -73.42 | -11,984.25 | -- |
| Revenue CAGR (3Y) %i | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -55.12 | -35.74 | -36.87 | -30.23 | -33.59 | -19.66 |
| ROA %i | -51.03 | -33.53 | -34.19 | -28.10 | -31.83 | -18.97 |
| ROIC %i | -58.70 | -38.61 | -40.95 | -34.63 | -38.58 | -22.82 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 15.38 | 22.42 | 21.93 | 19.66 | 24.75 | 37.28 |
| Quick ratioi | 15.04 | 22.06 | 21.56 | 19.31 | 24.14 | 36.50 |
| Debt / assetsi | 0.89 | 0.43 | 0.41 | 0.39 | 0.38 | 0.18 |
| LT debt / equityi | 0.68 | 0.30 | 0.28 | 0.24 | 0.21 | 0.09 |
| Interest coveragei | -15,793.00 | -23,671.00 | -45,889.00 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 08:20:29 · For reference only, not investment advice and not tailored to your situation.